The studies confirmed that the vaccine has a safety profile consistent with the licensed meningococcal vaccines of GSK. The ...
The story has been updated to correct the FDA approval date to Friday, February 14 On Friday, February 14, the FDA approved ...
Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...
Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...
The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 years against ...
GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy, tipped as one of its major launches for ...
Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...
A CDC vaccine advisory committee meeting scheduled for next week has been postponed. It was the first vaccine meeting since ...
The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active ...
The vaccine targets five major serogroups of Neisseria meningitidis (A, B, C, W, and Y) which commonly cause invasive meningococcal disease (IMD).1,2 Tony Wood, Chief Scientific Officer, ...
US regulators have approved a new meningitis vaccine developed by GSK, sparking cautious optimism for the sector in the wake ...
GSK has secured approval from the US Food and Drug Administration (FDA) for its new vaccine, Penmenvy, to protect against five meningococcal serogroups for individuals aged ten to 25. The vaccine ...